Celikyurt, Ipek KomsuogluMutlu, OguzUlak, GunerUyar, EmreBektas, EmineAkar, Furuzan YildizErden, Faruk2024-04-242024-04-2420142325-44162325-4394https://doi.org/10.12659/MSMBR.891168https://hdl.handle.net/11468/18353Background: Comorbid neurobehavioral disturbances and type-2 diabetes mellitus (T2DM) warrant immediate research attention. Exenatide, which is a potent and selective agonist for the glucagon-like peptide-1 (GLP-1), is used in the treatment of T2DM. Exenatide displays a multitude of effects in the central nervous system. The aim of this study was to investigate the anxiolytic- and antidepressant-like effects and analgesic effects of exenatide in a type-2 diabetic mouse model. Material/Methods: Modified elevated plus-maze test for anxiolytic- like, forced swimming test for depression-like behavior and hotplate test for neuropathy were used as behavioral tasks. Behavioral parameters were investigated in a streptozocin - (100 mg/kg, i.p.) and nicotinamide - (240 mg/kg, i.p.) induced type-2 diabetic mouse model. Exenatide (0.1 mu g/kg, s.c., twice daily) was administered for 2 weeks. Vehicle (control), diabetic, and exenatide-treated diabetic mice were tested. Results: Our results confirm that exenatide exerts anxiolytic- and antidepressant-like effects and might be effective in diabetic neuropathy in a diabetic mouse model. Conclusions: Exenatide may be a good candidate as a treatment option for depression, anxiety, and neuropathy in patients with type-2 diabetes.eninfo:eu-repo/semantics/openAccessAnti-Anxiety AgentsBehaviorAnimalDepressionDiabetes MellitusType 2Glucagon-Like Peptide 1Article20112117WOS:0002184773000162507641910.12659/MSMBR.891168N/A